Diasome Pharmaceuticals, Inc., a life sciences company focused on the development of novel therapies for the treatment of diabetes and other metabolic conditions, announced today the appointment of Peter Tollman to the board of directors.
“We are very pleased to welcome Peter to the board and are looking forward to working closely with him to advance Diasome’s leadership position as an innovator in diabetes care. Peter’s deep experience as a trusted advisor to pharma and biotech leadership teams will be invaluable to us, and we look forward to benefitting from his strategic insights and counsel,” said Robert Geho, Diasome’s CEO.
Dr. Tollman commented, “I am excited by this new relationship and by the opportunity to work closely with Diasome’s board and management team. In light of the ongoing challenges that people with type 1 and type 2 diabetes face globally, Diasome’s work has significant potential to solve long-standing problems in diabetes care. I look forward to contributing to the Company’s progress.”
Peter Tollman is Senior Partner Emeritus and Senior Advisor at Boston Consulting Group. He's also an adjunct professor at Columbia Business School and an advisor to several private equity firms and development-stage companies. Previously, Peter was Managing Director and Senior Partner in BCG's Boston office. He led BCG's CEO Advisory Practice globally, served as global leader of the firm’s Biopharmaceuticals Practice, and led its People and Organization Practice in the Americas. He was also a BCG Fellow, a prestigious thought-leadership post. As one of BCG's most experienced client-service partners, Peter has helped many of the world's leading corporations improve the competitiveness and performance of their organizations. Outside of BCG, Peter was a founding managing director of MPM Capital, a biotech venture-capital firm.
Diasome is the developer of Hepatocyte Directed Vesicles (HDV™), the world’s most clinically advanced liver targeting system for drugs used to treat diabetes. When combined with insulin, HDV™ enables preferential insulin delivery to liver hepatocytes in order to significantly reduce the risk of hypoglycemia in patients. The HDV system can be used with any form of insulin and is being tested in both injectable and oral insulin products. If approved, HDV-insulin would represent the most clinically differentiated commercially available rapid-acting pre-meal insulin.